https://mma.prnewswire.com/media/2598307/32a64817_10ba_407b_947c_76bd790799f6_Logo.jpg Why:Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations Plus securities you may be entitled […]

Paris, Oct. 06, 2025 (GLOBE NEWSWIRE) — Builds on positive top-line data from first cohort demonstrating significant reduction in urinary incontinence episodes Paris, France, October 6, 2025 – EG 427, a biotechnology company leading the development of pinpoint DNA medicines for prevalent chronic diseases in neurology, announced today that the U.S. Food and Drug Administration

(Brussels:NYXH),(NasdaqGM:NYXH), Nyxoah Announces First U.S. Commercial Patients Implanted with Genio(R) System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage Mont-Saint-Guibert, Belgium – October 6, 2025 7:00 CET / 1:00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a medical technology company that develops breakthrough treatment alternatives for Obstructive Sleep Apnea (OSA),

Nyxoah Announces First U.S. Commercial Patients Implanted with Genio(R) System GlobeNewswire October 06, 2025 Nyxoah Announces First U.S. Commercial Patients Implanted with Genio(R) System Early Commercial Launch Demonstrates Strong Physician Demand, Successful Pre-Authorizations, and Widespread Payor Coverage Mont-Saint-Guibert, Belgium – October 6, 2025 7:00 CET / 1:00 ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH), a

EG 427 Receives U.S. FDA Fast Track Designation for EG110A DNA Medicine in Neurogenic Bladder Patients GlobeNewswire October 06, 2025 Paris, Oct. 06, 2025 (GLOBE NEWSWIRE) — Builds on positive top-line data from first cohort demonstrating significant reduction in urinary incontinence episodes Paris, France, October 6, 2025 – EG 427, a biotechnology company leading the

NEXTDC Limited (ASX:NXT) (“NEXTDC” or “the Company”) today announces the appointment of Mr Jamaludin Ibrahim to the NEXTDC board as non-executive director, effective 1 November 2025. Mr Jamaludin has over 40 years of executive experience in the IT and telecommunications sectors, including 27 years as a CEO. Since retiring from executive roles in 2020, he

NEW YORK CITY, NY / ACCESS Newswire / October 6, 2025 / NEW YORK, NY / ACCESS Newswire / October 6, 2025 / If you suffered a loss on your PubMatic, Inc. (NASDAQ:PUBM) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/pubmatic-inc-lawsuit-submission-form?prid=170919&wire=1&utm_campaign=9

NEW YORK CITY, NY / ACCESS Newswire / October 6, 2025 / NEW YORK, NY / ACCESS Newswire / October 5, 2025 / If you suffered a loss on your Unicycive Therapeutics, Inc. (NASDAQ:UNCY) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

NEW YORK CITY, NY / ACCESS Newswire / October 6, 2025 / NEW YORK, NY / ACCESS Newswire / October 5, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of MoonLake Immunotherapeutics ("MoonLake") (NASDAQ:MLTX) concerning possible violations of federal securities laws. On September 29, 2025, MoonLake announced that its experimental

(NYSE:NX), Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Quanex To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Quanex between December 12, 2024 and September 5, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner